- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05073991
Incidence of Mortality and Complications After Lung Surgery, Open Thoracic Aortic Repair, TEVAR, EVAR.
October 23, 2021 updated by: Mahidol University
Incidence of Perioperative Mortality and Major Complications in Patients Who Underwent Lung Surgery, Open Thoracic Aortic Repair, Thoracic Endovascular Aortic Repair (TEVAR), and Endovascular Aortic Repair (EVAR). A Retrospective Study
Lung surgery, open aortic surgery, TEVAR, and EVAR are major operations that carry a higher incidence of perioperative mortality and complications compare to other surgery.
The study of the incidence of mortality and complications will help the hospital to benchmark with the others.
Also the study of the risk factors of mortality and major complications will help to improve the patients' outcomes.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
2224
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Sirilak Suksompong, MD
- Phone Number: 66891534806
- Email: sirilak.suk@mahidol.ac.th
Study Locations
-
-
Bangkok
-
Bangkoknoi, Bangkok, Thailand, 10700
- Recruiting
- Anesthesiology Department Siriraj Hospital
-
Contact:
- Sirilak Suksompong, M.D.
- Phone Number: 66891534806
- Email: sirilak.suk@mahidol.ac.th
-
Contact:
- Sirintip Swangwong, M.D.
- Phone Number: 66874535300
- Email: peach.in.town@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients who underwent one of these types of surgery 1) thoracic surgery, 2) open thoracic aortic surgery, 3) TEVAR and 4) EVAR
Description
Inclusion Criteria:
Patients underwent
- thoracic surgery
- open thoracic aortic surgery
- TEVAR
- EVAR
Exclusion Criteria:
- Emergency lung surgery
- Conversion from TEVAR to open thoracic surgery
- Conversion from EVAR to open aortic surgery
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Family-Based
- Time Perspectives: Retrospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Lung surgery
Patients underwent lung surgery.
|
Patients underwent lung surgery including wedge resection, lobectomy, segmentectomy, and pneumonectomy.
|
Open aortic suregry
Patients underwent open aortic surgery.
|
Patients underwent open thoracic surgery or thoracoabdominal aortic surgery.
|
Thoracic endovascular aortic repair (TEVAR)
Patients underwent TEVAR.
|
Patients underwent TEVAR.
|
Endovascular aneurysm repair (EVAR)
Patients underwent EVAR.
|
Patients underwent EVAR.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of mortality and major complications after lung surgery
Time Frame: 30 days
|
The mortality and major complications (CVS, CNS, RS and others) will be recorded.
|
30 days
|
Incidence of mortality and major complications after open aortic surgery
Time Frame: 30 days
|
The mortality and major complications (CVS, CNS, RS and others) will be recorded.
|
30 days
|
Incidence of mortality and major complications after TEVAR
Time Frame: 30 days
|
The mortality and major complications (CVS, CNS, RS and others) will be recorded.
|
30 days
|
Incidence of mortality and major complications after EVAR
Time Frame: 30 days
|
The mortality and major complications (CVS, CNS, RS and others) will be recorded.
|
30 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Risk factors of mortality and major complications after lung surgery
Time Frame: 30 days
|
To identify risk factors eg.
smoking, type of surgery, age, etc.
|
30 days
|
Risk factors of mortality and major complications after open aortic surgery
Time Frame: 30 days
|
To identify risk factors eg.
smoking, type of surgery, age, etc.
|
30 days
|
Risk factors of mortality and major complications after TEVAR
Time Frame: 30 days
|
To identify risk factors eg.
smoking, diagnosis, age, etc.
|
30 days
|
Risk factors of mortality and major complications after EVAR
Time Frame: 30 days
|
To identify risk factors eg.
smoking, age, etc.
|
30 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of postoperative delirium
Time Frame: 30 days
|
The patients with postoperative delirium required treatment will be described.
|
30 days
|
Incidence of low muscle mass
Time Frame: 7 days
|
Psoas muscle index will be used for the diagnosis of low muscle mass. Psoas muscle index = both psoas muscle area at L3 (from CT scan) divided by body surface area. Cut-off values of sarcopenia
|
7 days
|
Risk factors of postoperative stroke.
Time Frame: 30 days
|
To identify risk factors eg.
smoking, type of surgery, age, etc.
|
30 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 23, 2021
Primary Completion (Anticipated)
December 31, 2023
Study Completion (Anticipated)
December 31, 2023
Study Registration Dates
First Submitted
October 2, 2021
First Submitted That Met QC Criteria
October 2, 2021
First Posted (Actual)
October 12, 2021
Study Record Updates
Last Update Posted (Actual)
November 1, 2021
Last Update Submitted That Met QC Criteria
October 23, 2021
Last Verified
October 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 798/2564(IRB3)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on Lung surgery
-
Hopital FochCompleted
-
Deep BreezeUnknownLung CancerUnited States
-
Universität Duisburg-EssenRecruiting
-
University of UlmHeidelberg UniversityUnknownRespiration DisordersGermany
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedLung Diseases | Lung Diseases, Obstructive | Chronic Obstructive Pulmonary Disease | Emphysema
-
University of ZurichCompletedChronic Obstructive Pulmonary DiseaseSwitzerland
-
US Department of Veterans AffairsCompleted
-
Danish Pain Research CenterDOLORisk Consortium; Aarhus University HospitalCompletedChronic Neuropathic Pain, Postoperative | Chronic Pain, Postoperative | Chronic Chemotherapy-induced Neuropathic Pain | Chronic Chemotherapy-induced Pain | Chronic Chemotherapy-induced Peripheral NeuropathyDenmark
-
Rajiv Gandhi Cancer Institute & Research Center...Completed
-
National Taiwan University HospitalUnknownVentilator-associated Lung Injury | Acute Pulmonary Insufficiency Following Thoracic SurgeryTaiwan